Source BioScience PLC AMENDMENT - Form 8 (DD) - Source BioScience plc (9231J)
September 15 2016 - 3:30AM
UK Regulatory
TIDMSBS
RNS Number : 9231J
Source BioScience PLC
15 September 2016
AMMENT
Please be advised that this announcement replaces the version
previously released on 14 August 2016 under RNS number 8695J. The
number of share options held has been amended to 'nil'. All other
information remains unchanged.
FORM 8 (DD)
PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON
ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF
DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Mr Tim Metcalfe
(Finance Director
of Source BioScience
plc)
----------------------------------- ----------------------
(b) Owner or controller N/A
of interests and short
positions disclosed, if
different from 1(a):
The naming of nominee
or vehicle companies is
insufficient. For a trust,
the trustee(s), settlor
and beneficiaries must
be named.
----------------------------------- ----------------------
(c) Name of offeror/offeree Source BioScience
in relation to whose relevant plc
securities this form relates:
Use a separate form for
each offeror/offeree
----------------------------------- ----------------------
(d) Status of person making Person acting
the disclosure: in concert with
e.g. offeror, offeree, the offeree
person acting in concert
with the offeror/offeree
(specify name of offeror/offeree)
----------------------------------- ----------------------
(e) Date dealing undertaken: 13 September 2016
----------------------------------- ----------------------
(f) In addition to the N/A
company in 1(c) above,
is the discloser making
disclosures in respect
of any other party to
the offer?
If it is a cash offer
or possible cash offer,
state "N/A"
----------------------------------- ----------------------
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing
Class of relevant
security:
--------------------------- -------------------------------------
Interests Short positions
--------------------------- ----------------- ------------------
Number % Number %
--------------------------- ---------- ----- ------------- ---
(1) Relevant securities
owned and/or controlled: 1,606,154 0.4% nil -
--------------------------- ---------- ----- ------------- ---
(2) Cash-settled nil - nil -
derivatives:
--------------------------- ---------- ----- ------------- ---
(3) Stock-settled nil - nil -
derivatives (including
options) and agreements
to purchase/sell:
--------------------------- ---------- ----- ------------- ---
TOTAL: 1,606,154 0.4% nil -
--------------------------- ---------- ----- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Nil.
3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
(i) Party to an offer or person acting in concert (except for a
principal trader in the same group as a connected adviser)
Class of Purchase/sale Number of Price per
relevant securities unit
security
---------- -------------- ------------ ----------
n/a n/a n/a n/a
---------- -------------- ------------ ----------
(ii) Principal trader where the sole reason for the connection
is that the principal trader is in the same group as a connected
adviser
Class Purchases/ Total Highest Lowest
of relevant sales number price price
security of securities per unit per unit
paid/received paid/received
------------- ----------- --------------- --------------- ---------------
n/a n/a n/a n/a n/a
------------- ----------- --------------- --------------- ---------------
(b) Cash-settled derivative transactions
Class Product Nature of Number Price
of relevant description dealing of reference per unit
security e.g. e.g. opening/closing securities
CFD a long/short
position,
increasing/reducing
a long/short
position
------------- ------------- ---------------------- -------------- ----------
n/a n/a n/a n/a n/a
------------- ------------- ---------------------- -------------- ----------
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class Product Writing, Number Exercise Type Expiry Option
of descriptione.g. purchasing, of price e.g. date money
relevant call selling, securities per American, paid/
security option varying to unit European received
etc. which etc. per
option unit
relates
---------- ----------------- ------------- ------------ --------- ----------- ------- ----------
n/a n/a n/a n/a n/a n/a n/a n/a
---------- ----------------- ------------- ------------ --------- ----------- ------- ----------
(ii) Exercise
Class Product Exercising/ Number Exercise
of relevant description exercised of securities price
security e.g. call against per unit
option
------------- ------------- ------------ --------------- ----------
Ordinary Share Exercised 1,606,154 Nil
shares options
of 2 pence
each
------------- ------------- ------------ --------------- ----------
(d) Other dealings (including subscribing for new securities)
Class of Nature of dealing Details Price
relevant e.g. subscription, per unit
security conversion (if applicable)
---------- -------------------- -------- -----------------
n/a n/a n/a n/a
---------- -------------------- -------- -----------------
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement,
or any agreement or understanding, formal
or informal, relating to relevant securities
which may be an inducement to deal or refrain
from dealing entered into by the party
to the offer or person acting in concert
making the disclosure and any other person:
Irrevocable commitments and letters of
intent should not be included. If there
are no such agreements, arrangements or
understandings, state "none"
------------------------------------------------
None
------------------------------------------------
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or
understanding, formal or informal, between
the party to the offer or person acting
in concert making the disclosure and any
other person relating to:
(i) the voting rights of any relevant securities
under any option; or
(ii) the voting rights or future acquisition
or disposal of any relevant securities
to which any derivative is referenced:
If there are no such agreements, arrangements
or understandings, state "none"
--------------------------------------------------
None
--------------------------------------------------
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
------------------------------------- ---
Supplemental Form 8 (SBL) NO
------------------------------------- ---
Date of disclosure: 14 September 2016
--------------------- ---------------------
Contact name: Nick Ash (Company
Secretary)
--------------------- ---------------------
Telephone number: +44 (0) 115 973 9010
--------------------- ---------------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's dealing disclosure
requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DCCLIFLDAAIELIR
(END) Dow Jones Newswires
September 15, 2016 03:30 ET (07:30 GMT)
Source Bioscience (LSE:SBS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Source Bioscience (LSE:SBS)
Historical Stock Chart
From Nov 2023 to Nov 2024
